Galectin Therapeutics, Inc. (GALT) EPS Estimated At $-0.11

March 15, 2018 - By Vivian Park

 Galectin Therapeutics, Inc. (GALT) EPS Estimated At $ 0.11
Investors sentiment decreased to 0.67 in 2017 Q3. Its down 1.22, from 1.89 in 2017Q2. It dropped, as 7 investors sold Galectin Therapeutics, Inc. shares while 8 reduced holdings. 4 funds opened positions while 6 raised stakes. 3.22 million shares or 4.39% less from 3.37 million shares in 2017Q2 were reported.
Guggenheim Capital Ltd Liability Co invested 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Royal Bankshares Of Canada invested 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Goldman Sachs reported 0% stake. Us National Bank De holds 118,921 shares or 0% of its portfolio. Courage Capital Mgmt Limited has 130,000 shares for 0.19% of their portfolio. 103,436 are held by Morgan Stanley. Moreover, Bancorporation Of America De has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 7,603 shares. Montana-based Da Davidson has invested 0.03% in Galectin Therapeutics, Inc. (NASDAQ:GALT). 300 were accumulated by Tci Wealth Advsr. Geode Cap Mngmt Limited Liability invested 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Norris Perne And French Limited Liability Partnership Mi reported 30,500 shares. Buckingham Asset Mngmt Limited Com owns 50,000 shares. Susquehanna Int Grp Llp holds 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 168,648 shares. Cutter And Commerce Brokerage stated it has 54,600 shares or 0.05% of all its holdings. Blackrock has 200,378 shares for 0% of their portfolio.

Since January 25, 2018, it had 2 insider buys, and 2 sales for $2.64 million activity. CZIRR JAMES C had sold 244,444 shares worth $1.33M on Thursday, January 25. $1.33M worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) was sold by 10X Fund – L.P..

Analysts expect Galectin Therapeutics, Inc. (NASDAQ:GALT) to report $-0.11 EPS on March, 29 before the open.They anticipate $0.02 EPS change or 15.38 % from last quarter’s $-0.13 EPS. After having $-0.13 EPS previously, Galectin Therapeutics, Inc.’s analysts see -15.38 % EPS growth. The stock decreased 8.29% or $0.43 during the last trading session, reaching $4.76. About 376,023 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 62.09% since March 15, 2017 and is uptrending. It has outperformed by 45.39% the S&P500.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

Among 5 analysts covering Galectin Therapeutics (NASDAQ:GALT), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Galectin Therapeutics had 12 analyst reports since September 21, 2015 according to SRatingsIntel. As per Monday, March 28, the company rating was reinitiated by H.C. Wainwright. Roth Capital maintained it with “Buy” rating and $8.0 target in Thursday, January 4 report. On Monday, October 3 the stock rating was downgraded by FBR Capital to “Mkt Perform”. The firm has “Sell” rating given on Wednesday, September 28 by TH Capital. The firm has “Buy” rating by H.C. Wainwright given on Thursday, March 30. The rating was downgraded by Roth Capital on Wednesday, September 28 to “Sell”. The stock has “Buy” rating by H.C. Wainwright on Wednesday, June 14. On Monday, September 21 the stock rating was initiated by H.C. Wainwright with “Buy”. As per Thursday, September 29, the company rating was downgraded by H.C. Wainwright. The stock has “Buy” rating by Roth Capital on Thursday, December 7.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $172.02 million. The company's lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: which released: “Galectin Therapeutics to Present at BIO CEO & Investor Conference” on February 06, 2018, also with their article: “Galectin Therapeutics to Present at Two International Conferences in March” published on March 09, 2018, published: “Update On Galectin Therapeutics’ Potential Entry Into Cancer Market” on February 15, 2018. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: and their article: “Galectin Therapeutics Announces Record Date and Annual Stockholders Meeting …” published on March 05, 2018 as well as‘s news article titled: “Galectin Therapeutics Provides Corporate Update at Annual Meeting” with publication date: December 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.